PEPTIDE RESEARCH TOPIC

CJC-1295 Research Peptide

Explore CJC-1295 terminology, DAC and no-DAC distinctions, research context, comparisons, and handling information.

TOPIC OVERVIEW

About CJC-1295

Identity and names

CJC-1295 is the name used for a synthetic growth hormone-releasing hormone analogue developed for prolonged activity.

  • CJC 1295 and CJC1295 are spelling variants, while “CJC-1295 no DAC” is an inconsistent market label that may refer to a different GHRH-related sequence.

Compound type

The original CJC-1295 design includes a Drug Affinity Complex, or DAC.

  • DAC supports covalent association with circulating albumin; modified GRF 1-29 and products sold as no-DAC material should not be assumed to be the same molecule.

Mechanism

CJC-1295 acts at GHRH receptors on pituitary somatotroph cells.

  • Research examines growth-hormone release, IGF-1, pulsatile endocrine signaling, albumin binding, duration of exposure, and differences from ghrelin-receptor agonists.

Research focus and evidence

Small early controlled studies in healthy adults measured sustained pharmacodynamic changes while retaining pulsatile growth-hormone secretion.

  • Human evidence remains limited and does not establish broad clinical effectiveness, long-term safety, or combination protocols.

Regulatory status and limits

CJC-1295 is not generally approved as a therapeutic medicine and is prohibited in sport under current World Anti-Doping Agency rules.

  • Because supplier naming is inconsistent, sequence, molecular mass, and conjugation state must be confirmed before deciding which published evidence is relevant.
Topics covered
  • GHRH analog terminology
  • DAC and no-DAC distinctions
  • sequence verification
  • storage and stability
  • purity and supplier documentation
Common names and related terms: cjc-1295, cjc 1295, cjc1295, cjc-1295 dac, cjc-1295 no dac
EVIDENCE PROFILE

CJC-1295 Research Evidence

A concise view of registered clinical research, PubMed-indexed literature, evidence stage, and important limitations.

LAST VERIFIEDSeptember 30, 2026
Registered records1
Active studies0
Completed studies0
PubMed records33
Compound typeLong-acting GHRH analog
AliasesCJC1295, DAC:GRF
Evidence stageVery limited registered clinical evidence
U.S. regulatory contextNot FDA-approved
CLINICAL REGISTRY

Selected registered research

NCT00267527Phase 2 · Terminated

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

INDEXED LITERATURE

Selected PubMed records

PMID 163526832006 Mar · The Journal of clinical endocrinology and metabolism

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

PMID 414764242026 Jan · The American journal of sports medicine

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

PMID 309380692019 Aug · Drug testing and analysis

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

How to interpret this profile

Registry and publication counts describe discoverable records, not proof of effectiveness or safety. Study design, compound identity, population, endpoints, and regulatory context must be reviewed individually.

Primary sources: ClinicalTrials.gov · PubMedCounts are dated exact-term search snapshots, not evidence-quality scores. Related compounds, spelling variants, and non-indexed literature may not be included.

Displayed records are selected for relevance and recency; the page does not reproduce the complete source databases.

START HERE

Essential CJC-1295 guides

CJC-1295 KNOWLEDGE ARTICLESPage 1 of 25
01
KNOWLEDGE ARTICLE

Buy CJC-1295 No DAC: Sourcing, Dosage & Safety

Thinking about where to buy CJC-1295 No DAC? Learn how this research peptide is sourced, how it differs from DAC versions, and key safety facts.

↗
02
KNOWLEDGE ARTICLE

CJC 1295 Ipamorelin Flushing: Causes & Duration

CJC 1295 ipamorelin flushing is a common, short-lived reaction to this peptide stack. Learn why it happens, how long it lasts, and how to reduce it.

↗
04
KNOWLEDGE ARTICLE

CJC-1295 Ipamorelin: DAC or No DAC?

CJC-1295 ipamorelin DAC or no DAC? Compare half-life, dosing frequency, and GH release patterns to see which version fits a research protocol.

↗
15
KNOWLEDGE ARTICLE

CJC-1295 With DAC Dosage: Weekly Dosing Guide

Review CJC-1295 with DAC dosage evidence, original weight-based trials, concentration examples, no-DAC distinctions, and limits of personal protocols.

↗
16
KNOWLEDGE ARTICLE

Does CJC-1295 Work? What Research Shows

Does CJC-1295 work? Learn how this GHRH peptide raises growth hormone, how long results may take, dosing basics, safety, and legal status in the US.

↗
17
KNOWLEDGE ARTICLE

CJC 1295 With DAC Weekly Dosage: What to Know

CJC 1295 with DAC weekly dosage is commonly discussed in research settings. Learn typical protocols, half-life, and safety considerations for this peptide.

↗
18
KNOWLEDGE ARTICLE

CJC-1295 Without DAC & Ipamorelin Dosage Guide

Typical cjc 1295 without dac ipamorelin dosage ranges, injection timing, blend ratios, and weekly totals for research use, plus important safety notes.

↗
20
KNOWLEDGE ARTICLE

CJC-1295 DAC vs Ipamorelin: Key Differences

CJC-1295 DAC vs ipamorelin explained: how these two growth hormone peptides differ in half-life, receptor targets, dosing frequency, and stacking.

↗